🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New study in Ghana pilots HPV self-sampling for #CervicalCancer screening—a scalable, cost-effective approach to boost early detection in low-resource settings. A key step toward WHO’s 2030 elimination goal. #HPV #GlobalHealth #CancerPrevention #PublicHealth #HealthEquity #LMICs

Recent Cancer Control study validates the CGMH nomogram for predicting survival in metastatic #PancreaticCancer patients treated with nal-IRI + 5-FU/LV. A tool for personalized care in real-world settings. #Oncology #CancerResearch #GIoncology #RealWorldData #PrecisionMedicine

New Cancer Control study shows that the Modified Glasgow Prognostic Score (mGPS) can predict #osteoporosis risk in elderly cancer patients. A simple, cost-effective tool to guide early intervention and improve outcomes. #CancerCare #BoneHealth #mGPS #OncologyResearch #Turkiye

Intraoperative blood transfusions and hospital stays >3 days are linked to reduced survival in #OvarianCancer surgery. Study underscores the need for transfusion-sparing & enhanced recovery protocols. #Oncology #SurgicalOutcomes #CancerResearch

Cancer Control study compares two #MHRT regimens in early-stage #ProstateCancer (60 Gy/20f vs 70 Gy/28f). Both showed similar survival, but 70 Gy/28f had lower late urinary toxicity. Findings support MHRT as a safe, effective treatment. #RadiationOncology #oncology

#Docetaxel showed manageable toxicity & promising efficacy in #NSCLC patients post platinum ± ICI therapy. Pemetrexed-pretreated patients had better OS than paclitaxel-pretreated patients. Findings support tailored 2nd line NSCLC strategies. #Oncology #CancerResearch #LungCancer

Review article on #Immunotherapy for limited-stage small cell #LungCancer (LS-SCLC). Durvalumab after chemoradiotherapy is redefining outcomes, nearly doubling median survival (ADRIATIC trial). A turning point for LS-SCLC—and a call for biomarker-driven, precision immunotherapy.

New study highlights 5 key ways to improve pre-surgical education for head & neck cancer patients—incl. better communication, tailored resources, and peer support. A step toward more patient-centered cancer care. #HeadAndNeckCancer #OncologyCare #PatientEducation #CancerSupport

New study links GPX1 (rs1050450) variants to #OvarianCancer risk in #Turkish women: CC genotype = protective, TT genotype = 3x higher risk. Study highlights potential for genetic #Biomarkers in ovarian cancer risk assessment. #Genetics #CancerResearch #WomensHealth #Turkey

New study reports that Black and rural AYA cancer survivors in Kentucky face greater #FinancialToxicity—linked to worse mental health and more medical issues. Findings highlight need for equity-focused, tailored interventions. #CancerSurvivorship #HealthEquity #AYAOncology

🧬New Cancer Control study reports ANAPC1 as a key driver in #ColorectalCancer, promoting tumor growth and immune evasion. Low ANAPC1 levels = better response to #Immunotherapy. A potential #Biomarker & target for future CRC treatment. #CancerResearch #Oncology #PrecisionMedicine

🧠 MRI and NLR before treatment can predict long-term outcomes in rectal cancer patients with pCR after chemoradiotherapy. Low NLR & EMVI-neg = excellent prognosis. A step forward in risk-adapted care. #RectalCancer #Oncology #CancerResearch #PrecisionMedicine #Biomarkers #MRI

#MachineLearning model predicts 90-day unplanned cardiac readmissions in blood cancer patients. Findings supports smarter discharge planning & better outcomes. Study out in Cancer Control. #CardioOncology #BloodCancer #DigitalHealth #Oncology #PredictiveAnalytics

Serum albumin & lymphocyte count can predict response to neoadjuvant FLOT in geriatric #GastricCancer patients. Higher albumin = better response & survival. Routine blood tests may guide smarter treatment in older patients. #GeriatricOncology #CancerBiomarkers #Turkey #Oncology

Real-world data show that #Tucatinib + trastuzumab + capecitabine offers clinical benefit in heavily pretreated HER2+ metastatic #BreastCancer, even after T-DXd. Observations support the use of tucatinib-based therapy in later treatment lines. #HER2Positive #Oncology

In #BreastCancer patients with chemo ports (TIAPs), left-side insertion and high catheter tip position raise complication risk—especially malposition. Findings underscore the need for careful TIAPs placement. #Oncology #PatientSafety #VascularAccess #CancerCare

A 21-year retrospective study of #MaleBreastCancer shows most cases are hormone receptor-positive. Age >65 & advanced stage = worse survival. Treatment adherence, especially hormonal therapy, improves outcomes. #Oncology #CancerAwareness #BreastCancer #CancerResearch

New systematic review published in Cancer Control reveals that low income, education, and job inflexibility lead to delayed or missed #BreastCancer treatment in the US—worsening outcomes. Equity-focused policies are urgently needed. #HealthEquity #CancerCare #Oncology

New research shows that flexible trial design is key to addressing #FinancialToxicity in #CancerCare. The CREDIT study boosted enrollment 3x by dropping strict caregiver requirements, paving the way for real-world financial navigation programs.#OncoResearch #ImplementationScience

Partnering with Black churches, researchers boosted genetic literacy & trial interest in Detroit’s Black community. An unusual, yet powerful model for advancing equity in precision medicine. #HealthEquity #GeneticResearch #FaithBased #PrecisionMedicine #CancerDisparities